Abstract | INTRODUCTION: MATERIAL AND METHODS: From September 2005 to June 2009, 355 advanced-stage NSCLC patients were accrued to compare the SNP variants with the outcome of platinum-based chemotherapy. TaqMan RT-PCR was used to evaluate the SNPs of the XRCC3 codon241 (Thr/Met) and XPD codon751 (Lys/Gln) DNA repair genes. RESULTS: There was a lack of association between the studied SNPs and the response rate, progression-free survival or overall survival (OS) in the whole population. However, subgroup analysis revealed that XRCC3 241 Thr/Met or Met/Met allele was associated with marginally significantly longer OS than XRCC3 Thr/Thr allele (19.0 m vs. 12.5 m, p=0.081) in the patients treated with gemcitabine/ cisplatin or carboplatin (GP/GC) while it was correlated with a significantly shorter OS in the patients treated with non GP/GC (9.3 m vs. 16 m, p=0.003). XPD751 Lys/Lys had an association with statistical significantly longer OS than XPD751 Lys/Gln or Gln/Gln in the subgroup of elderly patients (14.10 m vs. 10 m, p=0.019) and patients with non- adenocarcinoma (12.6 m vs. 9 m, p=0.042). CONCLUSIONS: XRCC3 Thr241Met played an opposite role in predicting prognosis of chemotherapy in NSCLC patients according to the first-line regimens. XPD 751 Lys/ Lys might be a better prognostic marker of elderly or noncarcinoma NSCLC subgroup treated with platinum-based chemotherapy.
|
Authors | Xiaoxia Chen, Hui Sun, Shengxiang Ren, Vikramsingh Kim Curran, Ling Zhang, Songwen Zhou, Jie Zhang, Caicun Zhou |
Journal | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
(Clin Transl Oncol)
Vol. 14
Issue 3
Pg. 207-13
(Mar 2012)
ISSN: 1699-3055 [Electronic] Italy |
PMID | 22374424
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers, Pharmacological
- Biomarkers, Tumor
- DNA-Binding Proteins
- Platinum Compounds
- X-ray repair cross complementing protein 3
- Xeroderma Pigmentosum Group D Protein
- ERCC2 protein, human
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Biomarkers, Pharmacological
(metabolism)
- Biomarkers, Tumor
(genetics)
- Carcinoma, Non-Small-Cell Lung
(diagnosis, drug therapy, genetics, mortality)
- Clinical Trials as Topic
- DNA-Binding Proteins
(genetics)
- Disease Progression
- Drug Resistance, Neoplasm
(genetics)
- Female
- Genetic Association Studies
- Humans
- Lung Neoplasms
(diagnosis, drug therapy, genetics, mortality)
- Male
- Middle Aged
- Platinum Compounds
(administration & dosage)
- Polymorphism, Single Nucleotide
(physiology)
- Prognosis
- Survival Analysis
- Treatment Outcome
- Xeroderma Pigmentosum Group D Protein
(genetics)
|